{"id":3311,"date":"2026-07-12T18:21:31","date_gmt":"2026-07-12T18:21:31","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/?p=3311"},"modified":"2026-07-12T18:21:31","modified_gmt":"2026-07-12T18:21:31","slug":"new-hope-for-boys-with-duchenne-muscular-dystrophy-fda-grants-special-status-to-experimental-drug-tegacorat","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/new-hope-for-boys-with-duchenne-muscular-dystrophy-fda-grants-special-status-to-experimental-drug-tegacorat\/","title":{"rendered":"New Hope for Boys with Duchenne Muscular Dystrophy: FDA Grants Special Status to Experimental Drug Tegacorat"},"content":{"rendered":"

Gr\u00fcnenthal, a pharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA<\/a>) has given two special designations to its investigational drug, tegacorat, for treating Duchenne muscular dystrophy (DMD). These designations recognize tegacorat as a potential breakthrough for a rare disease and also as a treatment for children with DMD. Tegacorat is a new type of oral medication designed to offer an alternative to standard treatments like prednison<\/a>e, which are commonly used but come with significant side effects. Unlike traditional steroids, tegacorat is designed to focus more on reducing harmful inflammation while minimizing the risks linked to long-term steroid<\/a> use, such as weight gain, changes in behavior, and other health problems. While this has not yet been proven in clinical trials, researchers believe tegacorat could be more effective and safer than current treatments. Uli Br\u00f6dl, Chief Scientific Officer at Gr\u00fcnenthal, explained, “Today, families and doctors caring for boys with DMD have to carefully balance the benefits of treatment with the side effects. We hope tegacorat will provide a better long-term option that reduces inflammation effectively while causing fewer problems over time.” The FDA\u2019s designations are an important step forward in the development of tegacorat. Gr\u00fcnenthal is now preparing for a Phase 2 clinical trial to study the drug\u2019s effectiveness, safety, and tolerability in boys with DMD. The trial is expected to begin in late 2026 and will take place at medical centers in the United States and Europe. DMD is a serious genetic condition that affects about 1 in every 5,000 boys. It is caused by a missing or defective protein called dystrophin, which is essential for muscle strength and function. The disease leads to progressive muscle weakening, making it difficult for boys to move, breathe, and maintain a healthy heart<\/a>. Sadly, DMD is currently incurable, and most boys with the condition live only into their twenties or thirties. Existing treatments, including glucocorticoid steroids, can help slow the progression of the disease but often come with serious side effects, such as changes in appearance, weight gain, and behavioral issues.<\/p>\n","protected":false},"excerpt":{"rendered":"

Gr\u00fcnenthal, a pharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has given two special designations to […]<\/p>\n","protected":false},"author":0,"featured_media":3312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-3311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=3311"}],"version-history":[{"count":1,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3311\/revisions"}],"predecessor-version":[{"id":3319,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3311\/revisions\/3319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media\/3312"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=3311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=3311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=3311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}